NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Bausch Health Companies Inc. (BHC) Stock Analysis

Bausch Health Companies Inc. (BHC) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

BHC

$6.56

−$0.20 (−2.96%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BHC with… →

BHC Key Statistics

As of Sep 4, 2026
Trading
Open
$6.71
Previous Close
$6.76
Day's Range
6.52–6.72
52-Week Range
4.33–8.00
Volume
1.65M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.37
Valuation
Market Cap
$2.45B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
1.56
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.01
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.94
Financials (FY)
Revenue (FY)
$10.27B+6.66%
Net Income (FY)
$157.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.12%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
373.99M
1-Year Return
−9.02%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
3.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BHC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.61%
2025−13.77%
2024+0.50%
2023+27.71%
2022−77.25%
2021+32.74%
2020−30.48%
2019+61.99%
2018−11.12%
2017+43.11%
2016 (partial year)−35.32%

As of September 4, 2026.

BHC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.27B$157.00M1.5%
2024$9.63B−$46.00M−0.5%
2023$8.76B−$592.00M−6.8%
2022$8.12B−$225.00M−2.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.27B$7.25B$2.19B$157.00M1.5%
2024$9.63B$6.84B$1.85B−$46.00M−0.5%
2023$8.76B$6.20B$1.60B−$592.00M−6.8%
2022$8.12B$5.76B$1.39B−$225.00M−2.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BHC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricBHCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.232.300.1x the median
Profit margin−10.12%−3.14%7.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bausch Health Companies Inc. (BHC) is capitalised at $2.45B on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 20,300.

The 52-week range on file runs from $4.33 to $8.00. BHC last closed at $6.56 on September 4, 2026. That is −$0.20 (−2.96%) against the previous close. The latest close sits 51.5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $10.27B. Against the prior fiscal year total of $9.63B, that is a change of +6.66%. The same year closed with net income of $157.00M. Profit margin runs at −10.12%. That is 7 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −2.94.

Across the 4 fiscal years on file, revenue moves from $8.12B in 2022 to $10.27B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 1.56. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.01. Measured against sales, the shares trade at 0.23 times revenue. On price-to-sales that is 0.1 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −9.02%. Measured over 10 years, that is −13.74% a year compounded. The reported beta is 0.37. Daily returns over the trailing 10 years annualize to a volatility of 59.62%.

Growth & Income

No dividend is on file for BHC.

2026 is still running; the price is −5.61% year to date. Across the complete calendar years on file, 2019 returned +61.99% and 2022 returned −77.25%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Bausch Health Companies Inc. (BHC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bausch Health Companies Inc. BHC $2.45B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Bausch Health Companies Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bausch Health Companies Inc.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Visit website →